SynthesisScientific reports2018

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.

Jin-Hua Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.